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Abstract
Background: Several studies have been performed to investigate the relationship between psoriasis and epicardial
fat tissue (EFT). However, the number of patients of every single study is relatively small.
Objectives: We carried out a meta-analysis to evaluate whether EFT is associated with psoriasis.
Methods: A search of PubMed, Ovid Embase, Ovid Medline, the Cochrane Library and Chinese BioMedical
Literature Database (CBM) for controlled trials was done from inception to January 20th, 2016. Published trials that
included a psoriasis group and a control group without psoriasis with data for at least epicardial fat tissue (EFT)
were included. All statistical analyses were conducted using the Stata 12.0 (Stata Corporation, College Station, TX,
USA).
Results: There were 5 trials involving 731 patients. Patients with psoriasis showed significantly higher EFT than
control group (SMD: 0.86, 95 % CI: 0.27-1.46, P = 0.004).
Conclusions: Patients with psoriasis have higher EFT compared to control subjects without psoriasis.
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Background
Psoriasis is a chronic immune-mediated inflammatory
disease which affects 2–4 % of the population worldwide
[1]. It is characterized by sharply demarcated erythema-
tous plaque lesions with silvery white scales. A number
of literatures pointed that psoriasis is associated with
several cardiometabolic co-morbidities and can increase
the risk of cardiovascular disease (CVD) and cardiovas-
cular mortality [2–6].
Epicardial fat tissue (EFT) is visceral fat around the
heart and coronary vessels. Recent studies suggested
that EFT play a significant role in the development of
cardiovascular diseases through secreting several in-
flammatory adipocytokines (TNF-alpha, IL-6, adipocy-
tokines, and leptin) in potential paracrine or endocrine
mechanism [7, 8].
Psoriasis and EFT are both associated with CVD. Sev-
eral studies have been performed to investigate the rela-
tionship between psoriasis and EFT [9–13]. But, the
number of patients of every single study is relatively
small. In this study, we play a meta-analysis to evaluate
whether EFT is associated with psoriasis.
Materials and methods
The process of the meta-analysis was performed accord-
ing to the Cochrane Collaboration recommendations
[14]. The analytical results were reported according to
the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement [15].
Search strategy
A systematic search was made in the following data-
bases: PubMed, Ovid Embase, Ovid Medline, the
Cochrane Library and Chinese BioMedical Literature
Database (CBM). The search used the terms “epicardial
fat tissue”, “psoriasis [Mesh]” which were searched as
text words and as exploded medical subject headings
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where possible. Free text words were searched combined
with additional keywords: “epicardial adipose tissue”,
“epicardial fat”, “epicardial adipose”. No language restric-
tions were applied. The search included literatures pub-
lished until January 20th, 2016 with no lower date limit.
Data extraction and quality assessment
Data were abstracted and quality of studies was assessed
independently by two reviewers (Xiaoxue Wang, Zexin
Zhu). Disagreement on specific studies between the two
reviewers was resolved by consensus. Data were ex-
tracted from each study including the sample size and
mean difference ± SD in EFT, total cholesterol, low-
density lipoprotein (LDL), high-density lipoprotein
(HDL), triglycerides in both psoriasis and non-psoriasis
groups. Methodological study quality was assessed using
the Strengthening of Reporting of Observational Studies
in Epidemiology (STROBE) checklist of 22 items [16].
Including and excluding criteria
Studies investigating the association between EFT and
psoriasis were considered for this meta-analysis. And the
diagnosis of psoriasis was made according to clinical or
pathological examination. The studies should include at
least a psoriasis group and a control group. Abstracts,
letters, and case reports and studies without sufficient
formation on EFT were excluded. If the same samples
were used in multiple publications, the most recent and/
or the largest publication were included.
Statistical analyses
All statistical analyses were carried out using Stata 12.0
(Stata Corporation, College Station, TX, USA). Pooled
standard mean difference (SMD) or weighted mean
difference (WMD) with 95%CI were calculated using
either the fixed-effects model or random-effects model.
For each meta-analysis, the χ2 and I2 statistics were first
calculated to assess the heterogeneity of the included
studies. P < 0.1 and I2 > 50 % were considered significant.
For P < 0.1 and I2 > 50 %, the random-effects model was
utilized. Otherwise, data were evaluated using the fixed-
effects model. The risk of publication bias in this study was
evaluated by visual inspection of the symmetry of the
funnel plot. The significance of the pooled SMD or WMD
was rated by the Z-test. P < 0.05 was regarded as significant.
Results
Description of the studies
We have searched a total of 76 studies, and 5 studies left
after excluded. The full-texts had been carefully evaluated.
They were published from 2013 to 2015, all of them mea-
sured EFT in psoriasis and control group [9–13]. Totally
731 patients were enrolled in these studies. Among those,
349 patients with psoriasis compared with 382 subjects
without psoriasis (Fig. 1).
The patients in each study are ranging from 63 to 302.
EFT thickness was measured by echocardiography in 3
studies [9–11]. EFT was calculated as the area [12] or
volume [13] by computed tomography (CT) in 2 studies.
Fig. 1 Flowchart showing selection of publications
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Table 1 The characteristics of studies included in the meta-analysis
Study Arms Patients Gender
(M/F)









Sen. et al. 2013 [9] Psoriasis 65 39/26 41.1 ± 3.3 25.9 ± 2.8 17.5 ± 5.7 190 ± 46 163 ± 78 33 ± 9 132 ± 33 7.3 ± 0.5 mm Echocardiography 20
Non-
psoriasis
50 28/22 40.5 ± 3.8 25.5 ± 2.3 199 ± 37 172 ± 88 34 ± 7 121 ± 36 6.5 ± 0.5 mm Echocardiography
Zehra. et al. 2014 [10] Psoriasis 31 14/17 42 ± 11.1 28.1 ± 5.6 6.1 ± 4 206.1 ± 34.8 165.4 ± 75.3 47.9 ± 8.0 125.1 ± 30.5 6.4 ± 2.6 mm Echocardiography 19
Non-
psoriasis
32 13/19 41.1 ± 6.8 30.9 ± 9.9 198.6 ± 31.8 143.5 ± 60.6 43.3 ± 13.4 126.6 ± 28.0 5.1 ± 1.9 mm Echocardiography
Ahmet. et al. 2014 [11] Psoriasis 115 62/53 33.6 ± 6.0 26.1 ± 3.1 3.8 ± 4.1 185.4 ± 37.4 125.3 ± 77.3 49.2 ± 12.9 129.4 ± 33.7 5.7 ± 1.2 mm Echocardiography 20
Non-
psoriasis
60 28/32 32.5 ± 8.3 25.2 ± 3.2 179.1 ± 33.8 126.2 ± 67.0 48.4 ± 13.5 127.7 ± 26.1 4.1 ± 1.0 mm Echocardiography
Balci .et al. 2014 [12] Psoriasis 38 26/12 42.2 ± 15.0 28.8 ± 3.9 9.8 ± 9.3 203.1 ± 33.7 150.2 ± 74.4 136.2 ± 27.7 37.6 ± 9.9 13.8 ± 8.4 cm2 CT 19
Non-
psoriasis
38 26/12 39.8 ± 13.5 27.4 ± 4.2 185.2 ± 38.5 130.1 ± 62.6 124.4 ± 42.1 41.4 ± 8.9 9.7 ± 6.4 cm2 CT
Torres. et al. 2015 [13] Psoriasis 100 64/36 47.4 ± 10.8 28.6 ± 4.99 12.8 ± 8.0 206.5 ± 39.9 126.7 ± 72.6 129.1 ± 38.2 51.5 ± 13.2 101.4 ± 55.52 ml CT 21
Non-
psoriasis
202 130/72 54.4 ± 10.1 28.1 ± 4.17 NA NA NA NA 92.2 ± 38.33 ml CT
Continuous variables were presented as mean ± standard deviation (SD), and categorical variables were presented as frequencies with percentages
















Disease severity of psoriasis was quantified using the
Psoriasis Area and Severity Index (PASI) in all included
studies. These characteristics and quality assessment
assessed by the STROBE are listed in the Table 1.
We compared the EFT, serum level of total choles-
terol, LDL, HDL and triglycerides.
Epicardial fat tissue
All studies included reported EFT. Subgroup analysis
was performed depending on different measurement of
EFT (thickness, area and volume). Based on the great
heterogeneity between trials (I2 = 92 %, P < 0.001), ran-
dom effects meta-regression analysis was made. There
was a significant difference in the SMD between psoria-
sis and non-psoriasis groups (0.86, 95 % CI: 0.27-1.46,
P = 0.004) (Fig. 2).
Total cholesterol
Four studies reported the total cholesterol in the serum.
We made a fixed-effect pooled analysis based on the low
heterogeneity among the 4 trials (I2 = 48.4 %, P = 0.121).
There was no significant difference in the WMD between
Fig. 2 Forest plot showing standardized difference in means and 95 % CI of EFT between patients with psoriasis and control group
Fig. 3 Forest plot showing difference in means and 95 % CI of total cholesterol between patients with psoriasis and control group
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psoriasis and non-psoriasis groups (5.40 mg/dl, 95 % CI:
−1.65-12.44, P = 0.18) (Fig. 3).
Low-density lipoprotein
Four studies included reported LDL. According to the
low heterogeneity between trials (I2 = 0 %, P =0.421),
fixed-effect pooled analysis was made. There was no sig-
nificant difference in the WMD between psoriasis and
non-psoriasis groups (4.69 mg/dl, 95 % CI: −1.39-10.77,
P = 0.102) (Fig. 4).
High-density lipoprotein
Four studies reported HDL. Heterogeneity between trials
(I2 = 57.6 %, P = 0.069) is high, so random effects meta-
regression analysis was made. There was no significant
difference in the WMD between psoriasis and non-
psoriasis groups (−0.32 mg/dl, 95 % CI: −3.31-2.67,
P = 0.833) (Fig. 5).
Triglycerides
Four studies included reported triglycerides. Based on
the low heterogeneity between trials (I2 = 0 %, P = 0.403),
fixed-effect pooled analysis was made. There was no sig-
nificant difference in the WMD between psoriasis and
non-psoriasis groups (5.76 mg/dl, 95 % CI: −8.36-19.87,
P = 0.42) (Fig. 6).
Publication bias was not assessed because of limited
studies.
Discussions
The results of this meta-analysis suggest that EFT in-
creased significantly in psoriasis patients, compared with
non-psoriasis patients. However, there was no significant
Fig. 4 Forest plot showing difference in means and 95 % CI of LDL between patients with psoriasis and control group
Fig. 5 Forest plot showing difference in means and 95 % CI of HDL between patients with psoriasis and control group
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difference in total cholesterol, LDL, HDL and triglycer-
ides between the patients with and without psoriasis.
In recent years, many clinical studies found that psoriasis
patients are under a high risk of CVD. Neimann et al. [17]
conducted an epidemiology investigation of the relationship
between psoriasis and coronary heart disease based on the
General Practice Research Database (131,560 psoriasis
patients and 465,252 non-psoriasis patients). This study
showed that traditional risk factors for coronary heart
disease such as diabetes, hypertension, hyperlipidemia,
obesity and smoking are highly correlated with psoriasis. A
prospective study showed that patients with psoriasis is
under a higher relative risk (RR) of CVD compared with
the general population [18]. Alexandroff et al. put forward
that psoriasis is an independent risk factor for myocardial
infarction (MI) [19]. CVD and psoriasis have similar hist-
ology and molecular immune pathological basis [20], based
on Th1 cytokines (TNF alpha, IL - 2, IL - 10, IL - 12) [21].
Epicardial fat tissue (EFT) refers to the visceral fat
deposition in heart, and it developed from brown adipose
tissue in embryonic period. EFT has both protective effects
and adverse effects [22]. Its physiological role has not been
completely elucidated so far. Clinical research has proved
that the EFT is associated with cardiovascular risk factors.
Epicardial fat thickness in the metabolic syndrome popula-
tion is significantly higher than that of control group
[23, 24]. EFT is the source of cytokines which can induce
mononuclear cells infiltration into the vascular intima. This
process is an important step in the development of athero-
sclerosis. The expression of inflammatory gene in EFT is
higher than that in the subcutaneous adipose tissue in
cardiovascular disease patients. And EFT release more
inflammatory mediators such as, interleukin, MCP - 1 and
TNF alpha [25]. The thickness, area or volume of EFT can
be measured and evaluated by two-dimensional echocar-
diography, CT or magnetic resonance imaging (MRI).
To our knowledge, there are few studies explored the
relationship between EFT and psoriasis. However, the
causes of increased EFT in psoriasis patients are still
unknown. Chronic immune-mediated systemic inflamma-
tion may be liable for this phenomenon. This meta-
analysis also showed that no significant difference was
existed in the serum level of total cholesterol, LDL, HDL
and triglycerides between psoriasis patients and control
subjects. This demonstrates that increased EFT may be an
independent risk factor for psoriasis.
There is no multi-center, large sample size study about
the role of EFT in psoriasis published, and this meta-
analysis is the first time to investigate the relationship
between EFT and patients with psoriasis. This study may
have several possible limitations. Firstly, three studies
included [9, 10, 12] were small sample size. Secondly, all
the studies were performed as the cross sectional design
and the study groups were not under clinical follow-up.
Thirdly, the gold standard in measuring EFT is MRI.
Echocardiography is less accurate than CT or MRI, but
echocardiography is a noninvasive, less costly and con-
venient method. Another possible limitation of this ana-
lysis is the great heterogeneity of EFT between trials. That
may be caused by differences in measurement technology.
Conclusion
In conclusion, this meta-analysis has demonstrated that
there is no significant difference in total cholesterol,
LDL, HDL or triglycerides between psoriasis and con-
trol, but higher EFT in psoriasis group compared to con-
trol group. That may indicate that EFT is an
independent risk factor of psoriasis. This might give an
explanation for the relationship between psoriasis and
elevated risk of CVD. Moreover, increased EFT can also
provide a new clue for the future research of psoriasis.
Fig. 6 Forest plot showing difference in means and 95 % CI of triglycerides between patients with psoriasis and control group
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